Citations

Showing 10 of 107969 citations.

Transvenous Stimulation of the Renal Sympathetic Nerves Increases Systemic Blood Pressure: A Potential New Treatment Option for Neurocardiogenic Syncope
Madhavan, Malini , Ebrille, Elisa , Mulpuru, Siva K. , Mikell, Susan B. , Johnson, Susan B., Suddendorf, Scott H., Ladewig, Dorothy J., Gilles, Emily J., Danielsen, Andrew J., Asirvatham, Samuel J. , DeSimone, Christopher V. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 5, 2014 | Volume: 25 | Issue: 10 | Pages: 1115-1118

10.1111/jce.12466 | PMID 24902981 Get It

Renal Vein Stimulation Increases Blood PressureBackgroundNeurocardiogenic syncope (NCS) is a common and sometimes debilitating disorder, with no consistently effective treatment. NCS is due to a combination of bradycardia and vasodilation leading to syncope. Although pacemaker devices have been tried in treating the bradycardic aspect of NCS, no device‐based therapy exists to treat the coexistent vasodilation that occurs. The renal sympathetic innervation has been the target of denervation to treat hypertension. We hypothesized that stimulation of the renal sympathetic nerves can increase blood pressure and counteract vasodilation in NCS.Methods and ResultsHigh‐frequency stimulation (800–900 pps, 10 V, 30–200 seconds) was performed using a quadripolar catheter in the renal vein of 7 dogs and 1 baboon. A significant increase in blood pressure (BP; mean [SD] systolic BP 117 [±28] vs. 128 [±33], diastolic BP 75 [±19] vs. 87 [±29] mmHg) was noted during the stimulation, which returned to baseline after cessation of stimulation. The mean increase in systolic and diastolic BP was 13.0 (±3.3) (P = 0.006) and 10.2 (±4.6) (P = 0.08), respectively.ConclusionWe report the first ever study of feasibility and safety of high‐frequency electrical stimulation of the renal sympathetic innervation to increase BP in animal models. This has potential applications in the treatment of hypotensive states such as NCS.
The HELIOS Trial Protocol: A Phase III Study of Ibrutinib in Combination with Bendamustine and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
Hallek, Michael , Österborg, Anders , Chanan‐Khan, Asher , Mahler, Michelle, Salman, Mariya, Wan, Ying , Sun, Steven , Zhuang, Sen Hong, Howes, Angela, Kay, Neil E.

Mayo Clinic

Future Oncology | June 5, 2014 | Volume: 11 | Issue: 1 | Pages: 51-59

10.2217/fon.14.119 | PMID 24901734 Get It

Pyoderma gangrenosum: a possible cutaneous complication of levamisole‐tainted cocaine abuse
Keith, Phillip J., Joyce, Joel C. , Wilson, Barbara

Mayo Clinic

International Journal of Dermatology | June 5, 2014 | Volume: 54 | Issue: 9 | Pages: 1075-1077

10.1111/ijd.12212 | PMID 24898775 Get It

Calcitonin gene‐related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria
Kay, A.B., Ying, S., Ardelean, E., Młynek, A., Kita, Hirohito , Maurer, Marcus , Ying, S., Clark, Patricia M. , Kita, H

Mayo Clinic

Clinical & Experimental Allergy | June 5, 2014 | Volume: 44 | Issue: 8 | Pages: 1053-1060

10.1111/cea.12348 | PMID 24902612 Get It

Summary Background The mechanisms for producing weals in chronic spontaneous (idiopathic) urticaria (CSU) are incompletely understood. Leucocyte infiltration with vascular leakage and expression of the potent vasoactive agents' calcitonin gene‐related peptide ( CGRP ) and vascular endothelial growth factor ( VEGF ) are features of late‐phase allergic skin reactions, previously proposed as a model of CSU . Objective To measure CGRP and VEGF expression in lesional and non‐lesional skin from CSU patients and to compare results with a control group. Methods Eight paired biopsies (one from 4–8 h spontaneous weals and one from uninvolved skin) were taken from eight patients with CSU and nine control subjects and studied by immunohistochemistry and confocal microscopy. Results Lesional skin in CSU contained significantly more CGRP + and VEGF + cells than non‐lesional skin. No significant differences were observed in CGRP and VEGF expression between non‐lesional skin and controls. In lesional skin, VEGF and CGRP co‐localised to UEA‐1+ blood vessels. CGRP was also expressed by neutrophils and eosinophils and to a lesser extent by CD90 + fibroblasts, mast cells, CD 3 + and CD 68 + cells. CGRP and VEGF expression was not related to the duration of disease. Conclusion and Clinical Relevance Increased expression of CGRP and VEGF in lesional, but not uninvolved, skin indicates that these potent vasoactive agents may play a role in wealing and tissue oedema in CSU so representing novel targets in therapy.
The Effect of Cardiovascular Credentialed Pharmacists on Process Measures and Outcomes in Myocardial Infarction and Heart Failure
Dorsch, Michael P. , Lose, Jennifer M., DiDomenico, Robert J.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | June 5, 2014 | Volume: 34 | Issue: 8 | Pages: 803-808

10.1002/phar.1444 | PMID 24898104 Get It

ObjectiveThe purpose of this study was to determine if institutions with inpatient cardiovascular credentialed pharmacists exhibit improved quality measures for acute myocardial infarction (AMI) and heart failure (HF) care compared with institutions without inpatient cardiovascular credentialed pharmacists.MethodsWe conducted a multicenter, retrospective, cross‐sectional, matched case‐control study. Hospitals with at least one Added Qualification in Cardiology (AQCV) inpatient pharmacist were included in the case group. Each case group hospital was matched to hospitals without an AQCV pharmacist by region, number of cardiovascular discharges, and teaching hospital designation in a 1:3 ratio (case:control). The 34 AQCV hospitals were matched to 102 non‐AQCV hospitals. The proportions of discharges meeting HF and AMI process of care measures and 30‐day outcomes (readmission and mortality) for each hospital were determined from public data and compared between the case and control groups.ResultsHospitals with AQCV pharmacists performed better on process of care measures than hospitals without AQCV pharmacists (odds ratio 1.41, 95% confidence interval 1.25–1.58, p<0.0001, p<0.001 for heterogeneity), which was mainly driven by the aspirin on discharge for AMI and angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker on discharge for HF measures. No differences were observed between the groups for either readmission or mortality at 30 days.ConclusionsHospitals that used inpatient AQCV pharmacists performed better on process of care measures than hospitals that do not use inpatient AQCV pharmacists. However, improvements in process of care performance measures observed in AQCV hospitals did not translate into improved 30‐day clinical outcomes.
Radiosurgery is an Effective Treatment for Recurrent Esthesioneuroblastoma: A Multicenter Study
Link, Michael J. , Sheehan, Jason P. , Xu, Zhiyuan , Mathieu, David , Kano, Hideyuki , Lunsford, L. Dade , Van Gompel, Jamie J, Gompel, Jamie J. Van , Mathieu, David

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | June 4, 2014 | Volume: 75 | Issue: 06 | Pages: 409-414

10.1055/s-0034-1378151 | PMID 25452899 Get It

Orange Stains in a Healthy Neonate’s Diaper
Jeng, Jack Y., Franz, Walter B.

Mayo Clinic

Clinical Pediatrics | June 4, 2014 | Volume: 53 | Issue: 9 | Pages: 908-910

10.1177/0009922814536777 | PMID 24899631 Get It

When Drinking Makes the Tremor Worse: A Task‐Specific Orolingual Tremor
O’Gorman, Cullen , Bower, James H., Matsumoto, Joseph Y., Kantarci, Orhun H. , Kumar, Neeraj , O'Gorman, Cullen M, O'gorman, Cullen M

Mayo Clinic

Movement Disorders Clinical Practice | June 4, 2014 | Volume: 1 | Issue: 3 | Pages: 237-239

10.1002/mdc3.12041 | PMID 30363876 Get It

A comparison of fibromyalgia symptoms in patients with Healthy versus Depressive, Low and Reactive affect balance styles
Vincent, Ann , McAllister, Samantha J., Oh, Terry H., Hassett, Afton L. , Toussaint, Loren

Mayo Clinic

Scandinavian Journal of Pain | June 4, 2014 | Volume: 5 | Issue: 3 | Pages: 161-166

10.1016/j.sjpain.2014.05.001 | PMID 25067981 Get It

Abstract Background and aims Affect balance reflects relative levels of negative affect (NA) and positive affect (PA) and includes four styles: Healthy (low NA/high PA), Depressive (high NA/low PA), Reactive (high NA/high PA) and Low (low NA/low PA). These affect balance styles may have important associations with clinical outcomes in patients with fibromyalgia. Herein, we evaluated the severity of core fibromyalgia symptom domains as described by the Outcomes Research in Rheumatology-Fibromyalgia working group in the context of the four affect balance styles. Methods Data from 735 patients with fibromyalgia who completed the Brief Pain Inventory, Multidimensional Fatigue Inventory, Profile of Mood States, Medical Outcomes Sleep Scale, Multiple Ability Self-Report Questionnaire, Fibromyalgia Impact Questionnaire-Revised, Medical Outcomes Study Short Form-36, and Positive and Negative Affect Schedule were included in this analysis. Results The majority (51.8%) of patients in our sample had a Depressive affect balance style; compared to patients with a Healthy affect balance style, they scored significantly worse in all fibromyalgia symptom domains including pain, fatigue, sleep disturbance, dyscognition, depression, anxiety, stiffness, and functional status ( P = <.001 to .004). Overall, patients with a Healthy affect balance style had the lowest level of symptoms, while symptom levels of those with Reactive and Low affect balance styles were distributed in between those of the Depressive and Healthy groups. Conclusions and implications The results of our cross-sectional study suggest that having a Healthy affect balance style is associated with better physical and psychological symptom profiles in fibromyalgia. Futures studies evaluating these associations longitudinally could provide rationale for evaluating the effect of psychological interventions on affect balance and clinical outcomes in fibromyalgia.
Atrial Fibrillation and Stroke Prevention in Aging Patients
Freedman, Jane E. , Gersh, Bernard J.

Mayo Clinic

Circulation | June 4, 2014 | Volume: 130 | Issue: 2 | Pages: 129-131

10.1161/circulationaha.114.010873 | PMID 24895453 Get It